Your browser doesn't support javascript.
loading
Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group.
Swallow, Carol J; Strauss, Dirk C; Bonvalot, Sylvie; Rutkowski, Piotr; Desai, Anant; Gladdy, Rebecca A; Gonzalez, Ricardo; Gyorki, David E; Fairweather, Mark; van Houdt, Winan J; Stoeckle, Eberhard; Park, Jae Berm; Albertsmeier, Markus; Nessim, Carolyn; Cardona, Kenneth; Fiore, Marco; Hayes, Andrew; Tzanis, Dimitri; Skoczylas, Jacek; Ford, Samuel J; Ng, Deanna; Mullinax, John E; Snow, Hayden; Haas, Rick L; Callegaro, Dario; Smith, Myles J; Bouhadiba, Toufik; Stacchiotti, Silvia; Jones, Robin L; DeLaney, Thomas; Roland, Christina L; Raut, Chandrajit P; Gronchi, Alessandro.
Afiliação
  • Swallow CJ; Department of Surgical Oncology, Princess Margaret Cancer Centre/Mount Sinai Hospital, Toronto, ON, Canada. Carol.Swallow@sinaihealth.ca.
  • Strauss DC; Department of Surgery, University of Toronto, Toronto, ON, Canada. Carol.Swallow@sinaihealth.ca.
  • Bonvalot S; Sarcoma Unit, Department of Academic Surgery, Royal Marsden Hospital, Royal Marsden NHS Foundation Trust, London, UK. dirk.strauss@rmh.nhs.uk.
  • Rutkowski P; Department of Surgical Oncology, Institut Curie, PSL University, Paris, France.
  • Desai A; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Gladdy RA; Department of Surgery, University Hospitals Birmingham, Birmingham, UK.
  • Gonzalez R; Department of Surgical Oncology, Princess Margaret Cancer Centre/Mount Sinai Hospital, Toronto, ON, Canada.
  • Gyorki DE; Department of Surgery, University of Toronto, Toronto, ON, Canada.
  • Fairweather M; Sarcoma Department, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
  • van Houdt WJ; Department of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Stoeckle E; Department of Surgery, Brigham and Women's Hospital, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Park JB; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Albertsmeier M; Department of Surgery, Institut Bergonie, Bordeaux, France.
  • Nessim C; Department of Surgery, Samsung Medical Center, Seoul, South Korea.
  • Cardona K; Department of General, Visceral and Transplantation Surgery, Ludwig-Maximilians-Universität, University Hospital, Munich, Germany.
  • Fiore M; Department of Surgery, University of Ottawa, Ottawa, ON, Canada.
  • Hayes A; Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
  • Tzanis D; Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Skoczylas J; Sarcoma Unit, Department of Academic Surgery, Royal Marsden Hospital, Royal Marsden NHS Foundation Trust, London, UK.
  • Ford SJ; Department of Surgical Oncology, Institut Curie, PSL University, Paris, France.
  • Ng D; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Mullinax JE; Department of Surgery, University Hospitals Birmingham, Birmingham, UK.
  • Snow H; Department of Surgical Oncology, Princess Margaret Cancer Centre/Mount Sinai Hospital, Toronto, ON, Canada.
  • Haas RL; Department of Surgery, University of Toronto, Toronto, ON, Canada.
  • Callegaro D; Sarcoma Department, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
  • Smith MJ; Department of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Bouhadiba T; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Stacchiotti S; Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Jones RL; Sarcoma Unit, Department of Academic Surgery, Royal Marsden Hospital, Royal Marsden NHS Foundation Trust, London, UK.
  • DeLaney T; Department of Surgical Oncology, Institut Curie, PSL University, Paris, France.
  • Roland CL; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Raut CP; Department of Medical Oncology, Royal Marsden NHS Foundation Trust, London, UK.
  • Gronchi A; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Ann Surg Oncol ; 28(12): 7873-7888, 2021 Nov.
Article em En | MEDLINE | ID: mdl-33852100
ABSTRACT

BACKGROUND:

Retroperitoneal soft tissue sarcomas comprise a heterogeneous group of rare tumors of mesenchymal origin that include several well-defined histologic subtypes. In 2015, the Transatlantic Australasian RPS Working Group (TARPSWG) published consensus recommendations for the best management of primary retroperitoneal sarcoma (RPS). Since then, through international collaboration, new evidence and knowledge have been generated, creating the need for an updated consensus document.

METHODS:

The primary aim of this study was to critically evaluate the current evidence and develop an up-to-date consensus document on the approach to these difficult tumors. The resulting document applies to primary RPS that is non-visceral in origin, with exclusion criteria as previously described. The relevant literature was evaluated and an international group of experts consulted to formulate consensus statements regarding the best management of primary RPS. A level of evidence and grade of recommendation were attributed to each new/updated recommendation.

RESULTS:

Management of primary RPS was considered from diagnosis to follow-up. This rare and complex malignancy is best managed by an experienced multidisciplinary team in a specialized referral center. The best chance of cure is at the time of primary presentation, and an individualized management plan should be made based on the 29 consensus statements included in this article, which were agreed upon by all of the authors. Whenever possible, patients should be enrolled in prospective trials and studies.

CONCLUSIONS:

Ongoing international collaboration is critical to expand upon current knowledge and further improve outcomes of patients with RPS. In addition, prospective data collection and participation in multi-institution trials are strongly encouraged.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Retroperitoneais / Sarcoma / Neoplasias de Tecidos Moles / Neoplasias Ósseas Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Retroperitoneais / Sarcoma / Neoplasias de Tecidos Moles / Neoplasias Ósseas Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Canadá